Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: Ongoing RAV research with GS-9190


Guru

Status: Offline
Posts: 3249
Date:
Ongoing RAV research with GS-9190
Permalink  
 


Gilead's exploration is ongoing re: RAVS and development of using of other possible alternate NS5B drugs like SOF and GS-9190 in combo therapies.

Earlytrials on GS-9190, comparing classes of a "non-nucleoside inhibitor" (NNI) and "nucleoside inhibitors" (NI's) in newer DAA double and triple therapies, as compared to SOF being used in newer double/triple DAA therapies.

Journal of Viral Hepatitis

Antiviral Response and Resistance Analysis of Treatment-nave HCV-infected Patients Receiving Single and Multiple Doses of GS-9190

H. Mo; C. Hedskog; E. Svarovskaia; S.-C. Sun; I. M. Jacobson; D. M. Brainard; J. G. McHutchison; M. D. Miller

Disclosures

J Viral Hepat.2016;23(8):644-651.

... In the last several years, there has been expansion in development of direct-acting antiviral agents (DAAs) for treatment of chronic HCV infection. By combining two or more DAAs, high rates of sustained virologic response (SVR) have been achieved. Similar to other RNA viruses, HCV exists as a highly genetically diverse population within infected individuals.[2]HCV's RNA-dependent RNA polymerase lacks proofreading ability and generates approximately 103-105nucleotide mutations per replication cycle.[3]Accordingly, mutations conferring resistance to DAAs have been shown to pre-exist in the viral population and to be rapidly selected during monotherapy with NS3 or NS5A inhibitors.[4]Similar observations have been made with the class of non-nucleoside analogue (NNI) inhibitors of NS5B.[5]In contrast, resistance to nucleoside analogue inhibitors (NI) of NS5B is less frequent.[6]

The viral NS5B enzyme is an attractive target for drug development, where NIs target the highly conserved NS5B active site and NNIs target one of the four allosteric binding sites that are located within the thumb and palm domain of the protein.[7,8] Currently, there is one NI and one NNI approved on the market, sofosbuvir (SOF) and dasabuvir, respectively.



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 64 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

(SEE UPDATES IN BIO)

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.